|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's range||43.43 - 44.71|
|52-week range||25.04 - 48.82|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||N/A|
|Earnings date||01 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||47.44|
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.